Mohan Babu Appaiahgari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohan Babu Appaiahgari has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Krishna Kishore Inampudi
Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India
6 shared publications Tushar Kushwaha
4 shared publicationsDeepa Singh
3 shared publications- Deepak Sehgal
Department of Life Sciences, School of Natural Sciences Shiv Nadar Institution of Eminence Gautam Buddha Nagar Uttar Pradesh India
3 shared publications Kamal Baswal
3 shared publicationsRajkumar Kulandaisamy
3 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
Development of a G-Quadruplex-Forming DNA Aptamer Against EGFR-Driven Malignancies
- 29 October 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
Open AccessDevelopment of a G-Quadruplex-Forming DNA Aptamer Against EGFR-Driven Malignancies
- Open Access
- 12 October 2026
- Published by Springer Nature in Scientific Reports
Whole blood metabolomics reveals coordinated redox-one-carbon axis disruption in NSCLC: a pilot study in an Indian cohort
- 12 October 2026
- Published by Springer Nature in Scientific Reports
Open AccessWhole blood metabolomics reveals coordinated redox-one-carbon axis disruption in NSCLC: a pilot study in an Indian cohort
- Open Access
- 18 January 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (1) , 102452
Redefining NSP12 activity in SARS-CoV-2 and its regulation by NSP8 and NSP7
- 18 January 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (1) , 102452
Open AccessRedefining NSP12 activity in SARS-CoV-2 and its regulation by NSP8 and NSP7
- 2 January 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (5) , 1106-1123
Psoralidin acts as a dual protease inhibitor against PLpro and Mpro of SARS‐CoV‐2
The emergence of new coronavirus variants and concerns about vaccine effectiveness against these novel variants emphasize the need for broad‐spectrum therapeutics targeting conserved coronaviral non‐structural proteins. Accordingly, a virtual library of 178 putative inhibitors targeting SARS‐CoV‐2 Papain‐like protease (PLpro) was compiled through a systematic review of published literature and subsequently screened using molecular docking. Selected hits were analyzed for protease inhibitory activities, binding strength, and antiviral activities against HCoV229E‐based surrogate system and subsequently against SARS‐CoV‐2 for validation. Differences in potential modes of action were investigated using an HCoV229E‐based system, combined with in silico and biophysical methods against SARS‐CoV‐2 system. Of the 178 hits, 13 molecules showed superior docking scores against PLpro and met the inclusion criteria for further investigations. Of these, seven showed notable inhibitory activities against PLpro. Particularly, both Psoralidin and Corylifol‐A exhibited superior and, importantly, dual activities against SARS‐CoV‐2 Mpro. Both molecules were found to be biologically active against HCoV229E and SARS‐CoV‐2; however, Psoralidin exhibited more consistent effects and was relatively well‐tolerated. Detailed in silico analyses of their interactions with the two proteases identified differences in their modes of action, primarily due to differences in their binding of PLpro. Based on these findings, we propose Psoralidin as a potential candidate for further development as a broad‐spectrum antiviral and Corylifol‐A as an ideal candidate for lead optimization.
- 2 January 2025
- Published by Wiley in The FEBS Journal
- Vol. 292 (5) , 1106-1123
Psoralidin acts as a dual protease inhibitor against PLpro and Mpro of SARS‐CoV‐2
The emergence of new coronavirus variants and concerns about vaccine effectiveness against these novel variants emphasize the need for broad‐spectrum therapeutics targeting conserved coronaviral non‐structural proteins. Accordingly, a virtual library of 178 putative inhibitors targeting SARS‐CoV‐2 Papain‐like protease (PLpro) was compiled through a systematic review of published literature and subsequently screened using molecular docking. Selected hits were analyzed for protease inhibitory activities, binding strength, and antiviral activities against HCoV229E‐based surrogate system and subsequently against SARS‐CoV‐2 for validation. Differences in potential modes of action were investigated using an HCoV229E‐based system, combined with in silico and biophysical methods against SARS‐CoV‐2 system. Of the 178 hits, 13 molecules showed superior docking scores against PLpro and met the inclusion criteria for further investigations. Of these, seven showed notable inhibitory activities against PLpro. Particularly, both Psoralidin and Corylifol‐A exhibited superior and, importantly, dual activities against SARS‐CoV‐2 Mpro. Both molecules were found to be biologically active against HCoV229E and SARS‐CoV‐2; however, Psoralidin exhibited more consistent effects and was relatively well‐tolerated. Detailed in silico analyses of their interactions with the two proteases identified differences in their modes of action, primarily due to differences in their binding of PLpro. Based on these findings, we propose Psoralidin as a potential candidate for further development as a broad‐spectrum antiviral and Corylifol‐A as an ideal candidate for lead optimization.
- 10 September 2023
- Published by Wiley in The FEBS Journal
- Vol. 290 (23) , 5496-5513
Identification of a novel inhibitor of SARS‐CoV‐2 main protease: an in silico, biochemical, and cell‐based approach
The recurrent nature of coronavirus outbreaks, severity of the COVID‐19 pandemic, rapid emergence of novel variants, and concerns over the effectiveness of existing vaccines against novel variants have highlighted the need to develop therapeutic interventions. Targeted efforts to identify inhibitors of crucial viral proteins are the preferred strategy. In this study, we screened FDA‐approved and natural product libraries using in silico approach for potential hits against the SARS‐CoV‐2 main protease (Mpro) and experimentally validated their potency using in vitro biochemical and cell‐based assays. Seven potential hits were identified through in silico screening and were subsequently evaluated in SARS‐CoV‐2‐based cell‐free assays, followed by testing in the HCoV‐229E‐based culture system. Of the tested compounds, 4‐(3,4‐dihydroxyphenyl)‐6,7‐dihydroxy‐1‐isopropyl‐1H‐benzofuro[3,2‐b]pyrazolo[4,3‐e]pyridin‐3(2H)‐one (PubChem CID:71755304, hereafter referred to as STL522228) exhibited significant antiviral activity. Subsequently, its potential as a novel COVID therapeutic molecule was validated in the SARS‐CoV‐2‐culture system, where STL522228 demonstrated superior antiviral activity (EC50 = 0.44 μm) compared to Remdesivir (EC50 = 0.62 μm). Based on these findings, we report the strong anti‐coronavirus activity of STL522228, and propose that it as a promising pan‐coronavirus Mpro inhibitor for further experimental and preclinical validation.
- 10 September 2023
- Published by Wiley in The FEBS Journal
- Vol. 290 (23) , 5496-5513
Identification of a novel inhibitor of SARS‐CoV‐2 main protease: an in silico, biochemical, and cell‐based approach
The recurrent nature of coronavirus outbreaks, severity of the COVID‐19 pandemic, rapid emergence of novel variants, and concerns over the effectiveness of existing vaccines against novel variants have highlighted the need to develop therapeutic interventions. Targeted efforts to identify inhibitors of crucial viral proteins are the preferred strategy. In this study, we screened FDA‐approved and natural product libraries using in silico approach for potential hits against the SARS‐CoV‐2 main protease (Mpro) and experimentally validated their potency using in vitro biochemical and cell‐based assays. Seven potential hits were identified through in silico screening and were subsequently evaluated in SARS‐CoV‐2‐based cell‐free assays, followed by testing in the HCoV‐229E‐based culture system. Of the tested compounds, 4‐(3,4‐dihydroxyphenyl)‐6,7‐dihydroxy‐1‐isopropyl‐1H‐benzofuro[3,2‐b]pyrazolo[4,3‐e]pyridin‐3(2H)‐one (PubChem CID:71755304, hereafter referred to as STL522228) exhibited significant antiviral activity. Subsequently, its potential as a novel COVID therapeutic molecule was validated in the SARS‐CoV‐2‐culture system, where STL522228 demonstrated superior antiviral activity (EC50 = 0.44 μm) compared to Remdesivir (EC50 = 0.62 μm). Based on these findings, we report the strong anti‐coronavirus activity of STL522228, and propose that it as a promising pan‐coronavirus Mpro inhibitor for further experimental and preclinical validation.
- Open Access
Interaction of SCoV-2 NSP7 or NSP8 alone with NSP12 causes constriction of the RNA entry channel: Implications for novel RdRp inhibitor drug discovery
RNA-dependent RNA polymerase (RdRP) is a critical component of the RNA virus life cycle, including SCoV-2. Among the Coronavirus-encoded proteins, non-structural protein 12 ( NSP12 ) exhibits polymerase activity in collaboration with one unit of NSP7 and two units of NSP8 , constituting the RdRp holoenzyme. While there is abundant information on SCoV-2 RdRp-mediated RNA replication, the influence of interplay among NSP12, NSP7 , and NSP8 on template RNA binding and primer extension activity remains relatively unexplored and poorly understood. Here, we recreated a functional RdRp holoenzyme in vitro using recombinant SCoV-2 NSP12, NSP7 , and NSP8 , and established its functional activity. Subsequently, molecular interactions among the NSP s in the presence of a variety of templates and their effects on polymerase activity were studied, wherein we found that NSP12 alone exhibited notable polymerase activity that increased significantly in the presence of NSP7 and NSP8 . However, this activity was completely shut down, and the template RNA-primer complex was detached from NSP12 when one of the two cofactors was present. Through computational analysis, we found that the template RNA entry channel was more constricted in the presence of one of the two cofactors, which was relatively more constricted in the presence of NSP8 compared to that in the presence of NSP7 . In conclusion, we report that NSP7 and NSP8 together synergise to enhance the activity of NSP12 , but antagonise when present alone. Our findings have implications for novel drug development, and compounds that obstruct the binding of NSP7 or NSP8 to NSP12 can have lethal effects on viral RNA replication.
Open AccessInteraction of SCoV-2 NSP7 or NSP8 alone with NSP12 causes constriction of the RNA entry channel: Implications for novel RdRp inhibitor drug discovery
RNA-dependent RNA polymerase (RdRP) is a critical component of the RNA virus life cycle, including SCoV-2. Among the Coronavirus-encoded proteins, non-structural protein 12 ( NSP12 ) exhibits polymerase activity in collaboration with one unit of NSP7 and two units of NSP8 , constituting the RdRp holoenzyme. While there is abundant information on SCoV-2 RdRp-mediated RNA replication, the influence of interplay among NSP12, NSP7 , and NSP8 on template RNA binding and primer extension activity remains relatively unexplored and poorly understood. Here, we recreated a functional RdRp holoenzyme in vitro using recombinant SCoV-2 NSP12, NSP7 , and NSP8 , and established its functional activity. Subsequently, molecular interactions among the NSP s in the presence of a variety of templates and their effects on polymerase activity were studied, wherein we found that NSP12 alone exhibited notable polymerase activity that increased significantly in the presence of NSP7 and NSP8 . However, this activity was completely shut down, and the template RNA-primer complex was detached from NSP12 when one of the two cofactors was present. Through computational analysis, we found that the template RNA entry channel was more constricted in the presence of one of the two cofactors, which was relatively more constricted in the presence of NSP8 compared to that in the presence of NSP7 . In conclusion, we report that NSP7 and NSP8 together synergise to enhance the activity of NSP12 , but antagonise when present alone. Our findings have implications for novel drug development, and compounds that obstruct the binding of NSP7 or NSP8 to NSP12 can have lethal effects on viral RNA replication.